Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 13/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26986513 | 0.85 | CYP4F2 (0.48) | ATRCYP4F2CYP4A11HCRTR1HCRTR2 | |
| SCHEMBL26986543 | 0.82 | CYP4F2 (0.45) | ATRCYP4F2CYP4A11HCRTR1HCRTR2 | |
| SCHEMBL26986688 | 0.81 | CYP4F2 (0.46) | ATRCYP4F2CYP4A11HCRTR1HCRTR2 | |
| SCHEMBL22954588 | 0.81 | CYP4F2 (0.66) | ATRCYP4F2CYP4A11HCRTR1HCRTR2 | |
| SCHEMBL9977809 | 0.81 | CYP4F2 (0.47) | ATRCYP4F2CYP4A11 | |
| SCHEMBL13734367 | 0.80 | CYP4F2 (0.53) | ATRCYP4F2CYP4A11HCRTR1HCRTR2 | |
| SCHEMBL22954560 | 0.80 | CYP4F2 (0.54) | ATRCYP4F2CYP4A11HCRTR1HCRTR2 | |
| SCHEMBL16589766 | 0.79 | CYP4F2 (0.48) | ATRCYP4F2CYP4A11HCRTR1HCRTR2 | |
| SCHEMBL20893676 | 0.78 | ATR (0.41) | ATRCYP4F2CYP4A11HCRTR1HCRTR2 | |
| SCHEMBL20893669 | 0.77 | DRD4 (0.43) | ATRCYP4F2CYP4A11HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022251359-A1 | BICYCLIC INHIBITORS OF ALK5 AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| CN-109415341-B | Benzotriazole-derived alpha, beta unsaturated amide compounds as TGF-beta R1 inhibitor | 劲方医药科技(上海)有限公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3470409-B1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3470409-A1 | BENZOTRIAZOLE-DERIVED AND UNSATURATED AMIDE COMPOUND USED AS TGF- R1 INHIBITOR | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017215506-A1 | BENZOTRIAZOLE-DERIVED Α AND Β UNSATURATED AMIDE COMPOUND USED AS TGF-ΒR1 INHIBITOR | 南京明德新药研发股份有限公司 | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | TGFBR1, TGFBR2, TGFB1 | ATR 535/4885CYP4F2 3383/4885CYP4A11 1638/4885 |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | TGFBR1, TGFBR2, TGFB1 | ATR 618/4885CYP4F2 3410/4885CYP4A11 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.